Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Ondine Biomedical (LSE:OBI) reports no treatment-related serious adverse events in Phase 3 LANTERN data

AIM-quoted Ondine Biomedical (LSE:OBI) Inc. said on 28 October 2026 that additional safety and patient-reported tolerability results from its Phase 3 LANTERN trial had been presented at IDWeek 2026, as Poster P-1520. The poster was co-presented with the company's partner, HCA Healthcare's institute (HRI).

Ankur Sharma | 29 October 2026

4basebio PLC (LSE:4BB): What Could Move This AIM Stock Next as Investors Reassess Synthetic Dna Manufacturing And Commercial Adoption?

4basebio PLC operates in an environment where synthetic DNA manufacturing and commercial adoption. Its investment case depends not only on the size of its addressable market but also on management’s ability to translate activity into sustainable earnings and cash. Investors typically distinguish between a …

Ankur Sharma | 29 October 2026

Abingdon Health Plc (LSE:ABDX): What Could Move This AIM Stock Next as Investors Reassess Diagnostics Manufacturing And Customer Contracts?

Abingdon Health Plc operates in an environment where diagnostics manufacturing and customer contracts. Its investment case depends not only on the size of its addressable market but also on management’s ability to translate activity into sustainable earnings and cash. Investors typically distinguish between a …

Ankur Sharma | 29 October 2026

Haleon PLC (LSE:HLN): What Could Move This FTSE 100 Stock Next as Investors Reassess Consumer Health Brands?

Haleon PLC operates in an environment where consumer health brands, volume growth and margins. Its investment case depends not only on the size of its addressable market but also on management’s ability to translate activity into sustainable earnings and cash. Investors typically distinguish between …

Ankur Sharma | 29 October 2026

Bioventix Plc (LSE:BVXP): Why This London-Listed Stock Is in Focus and What Could Move Shares Next

Recent company developments, sector changes and expectations can influence the market even without a single decisive announcement. The most useful distinction is between information already reported and outcomes that remain contingent on management execution. For Bioventix Plc, the specific focus is royalty demand, assay …

Ankur Sharma | 29 October 2026

CRISM Therapeutics Corporation (LSE:CRTX): Why This London-Listed Stock Is in Focus and What Could Move Shares Next

Recent company developments, sector changes and expectations can influence the market even without a single decisive announcement. The most useful distinction is between information already reported and outcomes that remain contingent on management execution. For CRISM Therapeutics Corporation, the specific focus is clinical programme …

Ankur Sharma | 29 October 2026

HemoGenyx Pharmaceuticals Plc (LSE:HEMO): Why This London-Listed Stock Is in Focus and What Could Move Shares Next

Recent company developments, sector changes and expectations can influence the market even without a single decisive announcement. The most useful distinction is between information already reported and outcomes that remain contingent on management execution. For HemoGenyx Pharmaceuticals Plc, the specific focus is clinical development, …

Ankur Sharma | 29 October 2026

Inspiration Healthcare Group PLC (LSE:IHC): Why This London-Listed Stock Is in Focus and What Could Move Shares Next

Recent company developments, sector changes and expectations can influence the market even without a single decisive announcement. The most useful distinction is between information already reported and outcomes that remain contingent on management execution. For Inspiration Healthcare Group PLC, the specific focus is hospital …

Ankur Sharma | 29 October 2026

Sareum (LSE:SAR) upsizes oversubscribed retail offer, taking total raise to £3.34m

Sareum Holdings PLC (LSE:SAR), which describes itself as a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, published the result of its retail offer on 28 October 2026. The announcement follows the company's statements of 26 October 2026, including one …

Ankur Sharma | 29 October 2026

Ondine Biomedical (LSE:OBI): What the Latest Corporate Update Could Mean for Investors

Investors are assessing how company-specific execution could influence earnings quality and future valuation.

Ankur Sharma | 29 October 2026
Support

Hi! How can we help you today?

Loading…